A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

This looks slightly better than a coin flip. The study is randomized, blinded, placebo-controlled, and includes multiple BAY3283142 dose groups against one placebo arm, which raises the chance that at least one dose shows a usable efficacy signal. The primary endpoint, change in log UACR at Week 16, is a sensitive CKD biomarker and materially easier to move in Phase 2 than hard renal outcomes like eGFR slope or kidney failure. Stable background therapy should also reduce variability and help isolate drug effect. On the negative side, the mechanism appears novel and at least partly hemodynamic or vasodilatory; in CKD that can create hypotension or tolerability limits, and effect size is less predictable than for established renal drug classes. The enrolled CKD population may be heterogeneous and already receiving optimized standard care, which can compress incremental benefit. Estimated primary completion has passed but the trial still shows Active Not Recruiting, adding some execution or disclosure slippage risk. Overall, the endpoint and design support modestly favorable odds, but not a high-conviction readout.

BAY3283142 is a novel sGC activator targeting UACR reduction in CKD, a mechanism with strong class-level validation. Bayer's own runcaciguat showed ~45% UACR reduction vs placebo in its Phase 2a CONCORD trial, and Boehringer's avenciguat showed 15-23% UACR reduction across doses in Phase 2b trials with 500 patients. Both demonstrated statistical significance on the primary endpoint. The NO-sGC-cGMP pathway is well-validated for albuminuria reduction in CKD. BAY3283142 passed first-in-human trials successfully. The trial uses change in log(UACR) at 16 weeks—a responsive, well-accepted surrogate endpoint. Bayer has deep experience with sGC modulators. The primary completion date has passed by ~49 days with status 'Active Not Recruiting,' suggesting data collection is complete but results are not yet disclosed. Key risks: this is a new chemical entity that could have safety/tolerability issues (hypotension is a class concern), dose selection uncertainty is inherent in Phase 2, and the bar for 'positive' is ambiguous. The strong class precedent supports a modestly positive probability, estimated at 60%.

This is a Phase 2 CKD trial targeting albuminuria reduction via UACR at 16 weeks. The drug activates a vasodilatory protein mechanism, which is scientifically plausible but unproven in this indication. Phase 2 trials have historically high failure rates (~70%), and CKD/alburninuria trials face particular challenges due to heterogeneous patient populations and complex pathophysiology. The trial design appears sound with standard-of-care background therapy maintained. No prior efficacy data or safety signals are disclosed. The primary endpoint (log UACR change) is a validated surrogate marker. However, without Phase 1 data or any preliminary signal, intrinsic probability of positive results is below 50%. The recent primary completion date suggests data readout may be imminent, adding temporal uncertainty. Confidence is moderate due to standard Phase 2 uncertainties and lack of disclosed prior information.

This Phase 2 CKD trial by Bayer has a plausible mechanism targeting albuminuria reduction. The primary endpoint (UACR change at 16 weeks) is a well-accepted surrogate in nephrology. The patient population is well-defined with stable background therapy, reducing noise. Bayer is a capable sponsor. However, the intrinsic probability is only moderately above 50% due to the inherent uncertainty of a first efficacy readout for a novel compound in a complex disease. The 16-week duration is relatively short for kidney outcomes, and while UACR is predictive, it is not a clinical hard endpoint. The exclusion of high-risk cardiovascular patients may improve safety but also creates a less sick population. Operational risk is low as the trial is 'Active Not Recruiting' and past its primary completion date, suggesting data collection is complete.

Phase 2 placebo-controlled trial with multiple doses of novel BAY3283142 added to stable SOC in high-risk CKD patients (albuminuria, low eGFR). Primary endpoint (log UACR change at 16 weeks) is validated surrogate, sensitive to proven agents (RASi/SGLT2i), appropriately powered with equal group allocation. Patient population optimized for signal: elevated baseline UACR, stable therapies minimizing noise. Bayer's execution track record strong, double-blind design reduces bias. However, no prior human efficacy data; novel vascular relaxation mechanism unproven in CKD clinically. 16 weeks sufficient for UACR shift but limits durability assessment. Historical Phase 2 nephrology surrogate hit rate ~40-50%, discounted for first-in-class risks and operational completion 49 days past with no topline yet (low disclosure risk). Intrinsic yes probability 45%.

This Phase 2 trial for BAY3283142 in chronic kidney disease targets UACR reduction, a validated surrogate endpoint with well-established regulatory precedence. The sGC activator mechanism offers a differentiated approach from standard SGLT2 inhibitors and RAAS blockade, potentially providing additive efficacy. Critically, the primary completion date passed nearly 7 weeks ago, suggesting top-line data is imminent. Bayer's strategic investment in renal pipeline assets implies reasonable confidence in the mechanism. The inclusion/exclusion criteria are standard for this population, supporting execution feasibility. However, Phase 2 dose-ranging carries inherent failure risk, and without prior public disclosure of interim signals, confidence remains moderate. The probability estimates a slight lean toward a positive outcome based on mechanism plausibility and endpoint selection.

Phase 2 CKD trial with UACR reduction as primary endpoint completed primary completion 49 days ago but remains 'Active Not Recruiting,' suggesting data lock or analysis ongoing. BAY3283142 is a novel soluble guanylate cyclase stimulator—mechanism plausible for CKD given vascular effects, but Phase 2 asset with no prior Phase 2b/3 data disclosed. UACR is a validated surrogate but modest reductions often fail to translate to hard outcomes; 16-week duration is relatively short for CKD progression trials. Patient population (albuminuric CKD with stable background therapy) is appropriate but heterogeneous. No interim efficacy signals disclosed creates uncertainty. Bayer's execution record in cardiorenal is mixed. Disclosure risk elevated given completion date passed—results could emerge imminently. Overall, mechanistic promise tempered by early-phase uncertainty, surrogate endpoint limitations, and lack of visible efficacy hints. Intrinsic probability below 50%.

Bayer's Phase 2 ALPINE-1 trial evaluates the sGC activator BAY3283142 (nurandociguat) for CKD, with a primary endpoint of UACR reduction at 16 weeks. The intrinsic probability of success is high due to strong mechanistic rationale and precedent data. sGC activators induce vasodilation, which lowers intraglomerular pressure and predictably reduces albuminuria. Bayer’s earlier sGC activator, runcaciguat, has already established clinical proof-of-concept by reducing proteinuria in CKD patients. Furthermore, this trial is massive for a Phase 2 study (N=700), providing overwhelming statistical power to detect a significant dose-response or separation from placebo on a continuous surrogate endpoint (log UACR). While background standard-of-care (ACEi/ARB, SGLT2i) raises the bar for additive efficacy, the large sample size and dose-finding design mitigate this risk. Bayer’s deep expertise in the cardiorenal space (e.g., finerenone) further de-risks trial execution. Barring unexpected tolerability issues like severe hypotension limiting dose titration, the trial is highly likely to meet its primary endpoint.

The trial is a Phase 2 study evaluating the efficacy and safety of BAY3283142 in patients with Chronic Kidney Disease (CKD). The primary endpoint is a clinically relevant measure of urine albumin-creatinine ratio (UACR), which is a key indicator of kidney function. The study has a controlled design with a placebo group, and the treatment duration is 16 weeks, which is sufficient to assess the primary endpoint. The patient population has a clear indication for treatment, and the inclusion/exclusion criteria are well-defined. Although the study is still active and not yet completed, the design and execution appear robust, suggesting a potentially positive outcome.